代表性论文

Chenliang Shi; Yun Wu; Fengming Zou; Yuan Yuan; Chen Hu; Qingwang Liu; Chao Wu; Lijuan Shen; Aoli Wang; Wenchao Wang; Beilei Wang*; Jing Liu*; Qingsong Liu*; Discovery of a Novel Dihydroisoquinolinone Derivative as a Potent CDK9 Inhibitor Capable of Overcoming L156F Mutant for the Treatment of Hematologic Malignancies, Journal of Medicinal Chemistry, 2025, 68(8): 8106-8123.

Junjie Wang; Ziping Qi; Yun Wu; Aoli Wang; Qingwang Liu; Fengming Zou; Beilei Wang; Shuang Qi; Jiangyan Cao; Chen Hu; Chenliang Shi; Qianmao Liang; Li Wang; Jing Liu; Wenchao Wang; Qingsong Liu; Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitus., Signal Transduction and Targeted Therapy, 2023, 8(143).

Yun Wu; Ziping Qi; Beilei Wang; Junjie Wang; Qingwang Liu; Aoli Wang; Chenliang Shi; Bin Zhou; Qianmao Liang; Wenliang Wang; Fengming Zou; Shuang Q; Zuowei Wang; Li Wang; Wenchao Wang; Jing Liu*; Qingsong Liu*; Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 Diabetes, Journal of Medicinal Chemistry, 2022, 65(17):11818-11839.

Yun Wu; Beilei Wang; Junjie Wang; Shuang Qi; Fengming Zou; Ziping Qi; Feiyang Liu;Qingwang Liu; Cheng Chen; Chen Hu; Zhenquan Hu; Aoli Wang; Li Wang; Wenchao Wang; Tao Ren; Yujiao Cai; Mingfeng Bai; Qingsong Liu*; Jing Liu*; Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide(CHMFL-KIT-64)as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors, Journal of Medicinal Chemistry, 2019, 62(13): 6083-6101.

专利

刘青松；刘静；吴云；王蓓蕾；王傲莉；胡晨；刘青旺；邹凤鸣；王文超；王作伟；操江艳；时辰亮；王黎；二氢异喹啉酮和异吲哚啉酮衍生物及其用途，PCT/CN2021/125280

刘青松；刘静；吴云；汪文亮；王蓓蕾；齐紫平；王俊杰；王文超；亓爽；王黎；MST1激酶抑制剂及其用途，PCT/CN2019/110048

刘静；刘青松；吴云；王蓓蕾；齐紫平；邹凤鸣；刘青旺；王文超；陈程；王俊杰；王黎；一种喹啉结构的pan-KIT激酶抑制剂，PCT/CN2018/122307

承担项目

针对炎症性肠病的PGK1创新靶向药物研发，安徽省重点研究与开发计划，2023s07020018，2023-07 至 2026-07，100万元，在研，参与

哺乳动物Ste20样激酶MST1选择性抑制剂的发现研究, 安徽省自然科学基金青年项目, 1908085QH345,  2019-07 至 2021-06, 10万元, 结题，主持